EMCURE

Emcure Pharmaceuticals Share Price

 

 

Invest in Emcure Pharmaceuticals with 3.27X leverage

Invest with MTF

Performance

  • Low
  • ₹1,385
  • High
  • ₹1,465
  • 52 Week Low
  • ₹889
  • 52 Week High
  • ₹1,520
  • Open Price₹1,444
  • Previous Close₹1,427
  • Volume253,433

Investment Returns

  • Over 1 Month -0.73%
  • Over 3 Month + 6.43%
  • Over 6 Month + 5.67%
  • Over 1 Year -0.68%

Smart Investing Starts Here Start SIP with Emcure Pharmaceuticals for Steady Growth!

Invest Now

Emcure Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 33.7
  • PEG Ratio
  • 0.8
  • Market Cap Cr
  • 26,751
  • P/B Ratio
  • 5.6
  • Average True Range
  • 42.68
  • EPS
  • 42.32
  • Dividend Yield
  • 0.2
  • MACD Signal
  • 6.48
  • RSI
  • 53.59
  • MFI
  • 58.2

Emcure Pharmaceuticals Financials

Emcure Pharmaceuticals Technicals

EMA & SMA

Current Price
₹1,411.10
-15.4 (-1.08%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹1,397.29
  • 50 Day
  • ₹1,385.42
  • 100 Day
  • ₹1,365.39
  • 200 Day
  • ₹1,345.55

Resistance and Support

1420.37 Pivot Speed
  • R3 1,535.73
  • R2 1,500.37
  • R1 1,455.73
  • S1 1,375.73
  • S2 1,340.37
  • S3 1,295.73

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Emcure Pharmaceuticals manufactures and markets a wide range of pharmaceutical products, including generics, biosimilars, and injectables. With a global presence in 70+ countries, it focuses on affordable healthcare solutions across therapeutic areas like cardiology, oncology, and women’s health.

Emcure Pharmaceuticals Ltd has an operating revenue of Rs. 8,449.23 Cr. on a trailing 12-month basis. An annual revenue growth of 19% is outstanding, Pre-tax margin of 12% is healthy, ROE of 15% is good. The company has a reasonable debt to equity of 4%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 10% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 90 which is a GREAT score indicating consistency in earnings, a RS Rating of 78 which is FAIR indicating the recent price performance, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 30 indicates it belongs to a strong industry group of Medical-Supplies and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Emcure Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-11 Quarterly Results
2025-08-07 Quarterly Results
2025-05-22 Audited Results & Final Dividend
2025-02-06 Quarterly Results
2024-11-07 Quarterly Results
Date Purpose Remarks
2025-08-14 FINAL Rs.3.00 per share(30%)Final Dividend
View Emcure Pharmaceuticals Dividend History Arrow

Emcure Pharmaceuticals F&O

Emcure Pharmaceuticals Shareholding Pattern

77.88%
3.58%
0.48%
3.29%
0.01%
6.23%
8.53%

About Emcure Pharmaceuticals

  • NSE Symbol
  • EMCURE
  • BSE Symbol
  • 544210
  • Managing Director & CEO
  • Mr. Satish Ramanlal Mehta
  • ISIN
  • INE168P01015

Similar Stocks to Emcure Pharmaceuticals

Emcure Pharmaceuticals FAQs

Emcure Pharmaceuticals share price is ₹1,411 As on 26 December, 2025 | 07:19

The Market Cap of Emcure Pharmaceuticals is ₹26750.6 Cr As on 26 December, 2025 | 07:19

The P/E ratio of Emcure Pharmaceuticals is 33.7 As on 26 December, 2025 | 07:19

The PB ratio of Emcure Pharmaceuticals is 5.6 As on 26 December, 2025 | 07:19

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23